Aclidinium bromide 400 μg bid

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

CompletedNCT00868231

AstraZenecaChronic Obstructive Pulmonary Disease (COPD)

Start: 2009-03-31End: 2009-07-31Updated: 2017-01-04

Phase 3

Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

CompletedNCT01001494

AstraZenecaChronic Obstructive Pulmonary Disease (COPD)

Start: 2009-10-31End: 2010-11-30Updated: 2017-01-04

Related Papers

Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials

BMJ Open Respiratory Research2016-12-0118 citations

The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies.

2016-05-2317 citations

Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.

2011-09-0872 citations